La Jolla Pharmaceutical Company (LJPC) Return on Investment ROI from the second quarter of 2022 to second quarter of 2021 and for the year 2022, average high and low, overall ranking from Jun 30 2022 to Jun 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
La Jolla Pharmaceutical Company  (NASDAQ: LJPC)


La Jolla Pharmaceutical's ROI from its second quarter of 2022 to the second quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is La Jolla Pharmaceutical's ROI in the second quarter of 2022?
La Jolla Pharmaceutical Company achieved a return on average invested assets (ROI) of 4.79 % in its second quarter of 2022, this is above LJPC's average return on investment of -83.31%.
La Jolla Pharmaceutical Company invested over the 12 months ending in its second quarter of 2022 $83 million

ROI fell compared to the first quarter of 2022, despite the net income growth of 122800% from the first quarter of 2022.

Within the Healthcare sector 160 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2022 from 1863 to 1933.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter
Y / Y Investment Change TTM 16.73 % 14.82 % 5.15 % -15.31 % 3.37 %
Y / Y Net Income Change TTM 36.25 % - - - -
Investment (TTM) in Millions 83 80 84 84 84
Return On Investment (TTM) 4.79 % 6.32 % 23.85 % 16.23 % 4.11 %
LJPC's Overall Ranking # 1933 # 1863 # 334 # 769 # 1383
Seq. Investment Change TTM -0.31 % 0.74 % 7.74 % 7.88 % -1.94 %
Seq. Net Income Change TTM -24.31 % -73.33 % 58.38 % 326.12 % -
Net Income (TTM) in Millions 4 5 20 12 3

LJPC Company Profile >> Back to LJPC Roi Comparisons >> See Annual LJPC Return On Investment



Return On Investment LJPC's Ranking
Within: No.
Industry # 21
Sector # 161
Overall # 1933

Return On Investment Statistics
High Average Low
23.85 %
-83.31 %
-449.69 %
(Dec 31 2021)   (Jun 30 2014)







Financial Statements
La Jolla Pharmaceutical's II. Quarter Investments $ 83 Millions LJPC's Balance sheet
La Jolla Pharmaceutical's II. Quarter Income $ 2 Millions Quarterly LJPC's Income Statement
LJPC's Income by Division See LJPC's Income by Division


LJPC Annual Return On Investment (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Investments in Millions 84 60 108 174 101
Y / Y Investment Growth 39.55 % -44.36 % -38.07 % 72.15 % 65.45 %
Net Income in Millions 20 -39 -117 -199 -115
Y / Y Net Income Growth - - - - -
Annual Return On Investment 23.52 % -65.81 % -108.22 % -114.73 % -113.68 %


Annual Roi Comment
In the fiscal year 2021 ROI improved to 23.52 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LJPC's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LJPC's Competitors
Subscribers only: Roi for La Jolla Pharmaceutical's Suppliers
Subscribers only: Return On Investment for LJPC's Customers

Other Ratios
LJPC's Roa LJPC's Inventory Turnover Ratio LJPC's Growth Rates LJPC's Dividend Statistics
LJPC's Profitability Ratios LJPC's Asset Turnover Ratio LJPC's Dividend Growth
LJPC's Roe LJPC's Valuation Ratios LJPC's Financial Strength Ratios LJPC's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2022, within Healthcare Sector ROI
Xoma Royalty Corporation  13.13 %
Alpha Pro Tech Ltd   12.75 %
United Therapeutics Corporation  12.70 %
Assertio Holdings inc   12.67 %
Quest Diagnostics Inc  12.64 %
Carlisle Companies Incorporated  12.36 %
Docgo Inc   12.35 %
Bio techne Corp  12.03 %
Hca Healthcare Inc   11.77 %
Intuitive Surgical Inc   11.71 %
Abbvie Inc   11.21 %
3m Company  11.14 %
Patterson Companies Inc   11.09 %
Staar Surgical Co  11.03 %
Henry Schein Inc   10.85 %
Bruker Corporation  10.81 %
Palisade Bio Inc   10.78 %
Labcorp Holdings Inc   10.71 %
Regenxbio Inc   10.61 %
Pro dex Inc   10.57 %
Masimo Corp  10.52 %
Meridian Bioscience Inc   10.51 %
Chemomab Therapeutics Ltd   10.45 %
Eagle Pharmaceuticals inc   10.38 %
Nature s Sunshine Products inc   9.95 %
Fonar Corporation  9.82 %
Horizon Therapeutics Public Limited Company  9.71 %
Bristol myers Squibb Company  9.68 %
Atricure Inc   9.64 %
Orgenesis Inc   9.33 %

Date modified: 2026-09-08T15:10:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.